David Cachia, MD
Neurology · Worcester, MANPI 1336304526
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,900 of the $8,718 with a category attached, or 79.1%. Redhill Biopharma Inc. accounts for 68.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $6,000 and has fallen 75.0% since, to $1,500 in 2025.
Across 6 payments — averaging $1452.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Redhill Biopharma Inc.$6K
- Novocure Inc.$2K
- Bayer$900
- Agios Pharmaceuticals, Inc.$185
- Telix Pharmaceuticals$83
- GT Medical Technologies, Inc$50
Across 62 payments — averaging $4464.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$211K
- Agios Pharmaceuticals, Inc.$42K
- Servier Pharmaceuticals LLC$16K
- Servier Bioinnovation$8K
What the payments were for
- Consulting fees$6,90079%
- Speaking & faculty fees$1,50017%
- Food & beverage$3184%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Redhill Biopharma Inc. | 1 | $6,000 |
| Novocure Inc. | 1 | $1,500 |
| Bayer | 1 | $900 |
| Agios Pharmaceuticals, Inc. | 1 | $185 |
| Telix Pharmaceuticals | 1 | $83 |
| GT Medical Technologies, Inc | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune Gio$1,500
- Vitrakvi$900
How this compares
$8,718 in reported general payments places this provider in the 75th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 41 | $1,051 |
| Zonisamide | 11 | $346 |
| Lacosamide | 15 | $309 |
| Prochlorperazine Maleate | 11 | $248 |
| Dexamethasone | 16 | $190 |
| Ondansetron Hcl | 15 | $131 |
Paid to pharmacies, not to this prescriber.
Other neurology in Worcester
- Herbert MarkleyWorcester$183K
- Carolina IoneteWorcester$144K
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.